Tackling dementia

Dementia is stealing the lives of >55 million people worldwide.

There's no cure - and the failure rate in late stage clinical trials is >95% despite $ billions spent on R&D.

It's time to do things differently.

Why has progress been so slow?

• 30% misdiagnosis rate in early dementia

• Intervening too late - brain disease starts up to 15 years before symptoms appear.

People with different conditions are treated the same

Good drugs don't work if given to people who can't benefit from them

Innovation

Prodromic delivers early prediction for dementia

Current approach

With Prodromic

Patients with mild cognitive symptoms can't be separated, so treatment can't be tailored.

We separate patients at their first assessment, using AI to predict their future trajectory.

Up to half of patients are stable, so don't need costly and invasive tests or stressful follow ups.

Patients on different trajectories can have tailored interventions that balance risks and benefits.

Accelerating the search for new treatments

Prodromic's solutions can identify the right patients for clinical trials to deliver new treatments faster and at lower cost.

Our stratification technology is validated on a large scale randomised clinical trial of an Alzheimer's drug.

Using Prodromic's technology means:

• Fewer patients needed

• Higher statistical power

• Lower costs, and faster time to market

• Early-stage patients who actually have progressive disease

• Patients within the "intervention window" for a particular drug (not too early, not too late).

Research papers

Prodromic is built on a decade of innovation driven from Cambridge. The work underpinning our technology has been published in a series of papers in leading, international peer-reviewed journals:

Giorgio et al (2020) Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease. Neuroimage: Clinical 26, 102199

Giorgio et al (2022) A robust and interpretable machine learning approach using multimodal biological data to predict future pathological tau accumulation. Nature Communications 13, 1881

Lee et al (2024) Robust and interpretable AI-guided marker for early dementia prediction in real-world clinical settings. The Lancet: eClinicalMedicine 74, 102725

Vaghari et al (2025) AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer's Disease clinical trial. Nature Communications.

Coverage of our science

BBC News: AI may diagnose dementia in a day

The Times: AI could diagnose dementia before symptoms show

Sky News: New AI tool could be a game-changer in battle against Alzheimer's

Alan Turing Institute: AI could detect dementia after single brain scan

University of Cambridge: AI outperforms tests at predicting progress of Alzheimer's Disease